Evrcore ISI Boosts PT on Walgreens Boots (WBA) to $95; Confidence in Management is Increasing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Walgreens Boosts Alliance (WBA) PT Raised to $105 at Leerink Partners
July 9, 2015 5:50 PM EDTLeerink Partners analyst David Larsen reiterated his Outperform rating and boosted his price target on Walgreens Boosts Alliance (NASDAQ: WBA) to $105.00 (from $95.00) after the company reported "excellent" F3Q:15 results.
Larsen commented, "Since this is the first quarter with WBA reporting as a single,... More
Walgreen Boots Alliance (WBA) Tops Q3 EPS by 15c; Appoints New CEO; Boosts Dividend
July 9, 2015 7:02 AM EDTWalgreen Boots Alliance (NASDAQ: WBA) reported Q3 EPS of $1.02, $0.15 better than the analyst estimate of $0.87. Revenue for the quarter came in at $28.8 billion versus the consensus estimate of $29.63 billion.
Executive Vice Chairman and CEO Stefano Pessina said, In just six months since the strategic combination that formed Walgreens Boots Alliance, we are beginning to make progress in our operations, as we were able to deliver another strong quarter. Our Retail Pharmacy USA division produced a solid increase in comparable prescriptions filled in the quarter, along with improved retail front-end margins and very good... More
